Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Purchases $32,000.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) CEO Vishwas Seshadri purchased 10,000 shares of Abeona Therapeutics stock in a transaction dated Thursday, April 25th. The stock was acquired at an average price of $3.20 per share, for a total transaction of $32,000.00. Following the completion of the transaction, the chief executive officer now owns 538,260 shares in the company, valued at approximately $1,722,432. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Abeona Therapeutics Stock Down 5.6 %

Shares of NASDAQ:ABEO opened at $3.91 on Thursday. The company has a market cap of $106.94 million, a PE ratio of -1.52 and a beta of 1.49. The company’s 50-day moving average price is $7.11 and its 200 day moving average price is $5.62. Abeona Therapeutics Inc has a fifty-two week low of $2.83 and a fifty-two week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, equities analysts anticipate that Abeona Therapeutics Inc will post -2.14 EPS for the current year.

Wall Street Analysts Forecast Growth

ABEO has been the topic of several recent research reports. StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $36.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, April 23rd.

Hedge Funds Weigh In On Abeona Therapeutics

Large investors have recently bought and sold shares of the stock. Simplex Trading LLC increased its stake in Abeona Therapeutics by 1,889.9% during the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 13,418 shares during the period. Jump Financial LLC acquired a new position in Abeona Therapeutics during the 4th quarter valued at about $199,000. Schonfeld Strategic Advisors LLC acquired a new position in Abeona Therapeutics during the 3rd quarter valued at about $648,000. Worth Venture Partners LLC increased its stake in Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock valued at $1,184,000 after buying an additional 121,969 shares during the period. Finally, Barclays PLC increased its stake in Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock valued at $1,564,000 after buying an additional 185,638 shares during the period. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.